MGB CONSULTING
- Active Clients
- 8
- TTM Spend
- $541,500
- Total Filings
- 40
- Active Since
- 2025
trailing 4 reported quarters
income + expenses, last 12mo
25 in the last 12 months
2 years with filings
Income & Lobbyist Activity Last 10 years, by quarter
Clients from the last four reported quarters (8) · ranked by reported income and expenses
| Client | Reported $ | Filings | Share |
|---|---|---|---|
| ENDEAVOR BIOMEDICINES | $153.0K | 3 | 28.3% |
| ELEMENT BIOSCIENCES | $122.0K | 3 | 22.5% |
| ACT FOR ULTRA RARE | $75.0K | 3 | 13.9% |
| HUNTINGTON'S DISEASE SOCIETY OF AMERICA | $52.5K | 4 | 9.7% |
| BEAM THERAPEUTICS | $51.0K | 3 | 9.4% |
| ULTRAGENYX PHARMACEUTICAL | $38.0K | 2 | 7.0% |
| TAYSHA GENE THERAPIES | $30.0K | 4 | 5.5% |
| ARPA-H GO | $20.0K | 3 | 3.7% |
Issues lobbied last four reported quarters
| Issue | Activities | Share |
|---|---|---|
HCR
Health Issues
|
17 | 85.0% |
MED
Medical/Disease Research/Clinical Labs
|
3 | 15.0% |
Government entities contacted last four reported quarters
| Entity | Contacts | Share | Type |
|---|---|---|---|
| HOUSE OF REPRESENTATIVES | 15 | 41.7% | Congress |
| SENATE | 13 | 36.1% | Congress |
| Food & Drug Administration (FDA) | 5 | 13.9% | Agency |
| Intl Trade Administration (ITA) | 3 | 8.3% | Agency |
Revolving door lobbyists active in the last 12 months
0 of 1 lobbyist (0%) listed a prior covered government position on a lobbying filing.
Political contributions semiannual LD-203 reports by the firm and its lobbyists
2 reports on file for 2025 (latest version of each); 0 reported no contributions.
Itemized by year
| Year | Items | Total |
|---|---|---|
| 2025 | 2 | $1,000 |
Largest recipients, 2025
| Recipient | Items | Total |
|---|---|---|
| DR. RICHARD PAN honoring Dr. Richard Pan | 1 | $500 |
| DR. RICHARD PAN FOR CONGRESS honoring Dr. Richard Pan | 1 | $500 |
Filings 40 total
| Posted | Period | Client | Type | Income | Expenses | Activities | Lobbyists |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | 2026 Q2 | ARPA-H GO | 2nd Quarter - Report |
$12.5K | — | 1 | 1 |
| 2026-07-17 | 2026 Q2 | ACT FOR ULTRA RARE | 2nd Quarter - Report |
$37.5K | — | 1 | 1 |
| 2026-07-17 | 2026 Q2 | HUNTINGTON'S DISEASE SOCIETY OF AMERICA | 2nd Quarter - Termination (No Activity) |
$7.5K | — | 0 | 0 |
| 2026-07-17 | 2026 Q2 | TAYSHA GENE THERAPIES | 2nd Quarter - Report (No Activity) |
$20.0K | — | 0 | 0 |
| 2026-07-17 | 2026 Q2 | BEAM THERAPEUTICS | 2nd Quarter - Termination (No Activity) |
— | — | 0 | 0 |
| 2026-07-17 | 2026 Q2 | ENDEAVOR BIOMEDICINES | 2nd Quarter - Report |
$51.0K | — | 1 | 1 |
| 2026-07-17 | 2026 Q2 | ELEMENT BIOSCIENCES | 2nd Quarter - Report |
$44.0K | — | 2 | 1 |
| 2026-04-20 | 2026 Q1 | ARPA-H GO | 1st Quarter - Report |
$7.5K | — | 1 | 1 |
| 2026-04-20 | 2026 Q1 | ARPA-H GO | Registration |
— | — | 1 | 1 |
| 2026-04-20 | 2026 Q1 | ULTRAGENYX PHARMACEUTICAL | 1st Quarter - Termination |
— | — | 1 | 1 |
Lobbyists active in the last 12 months (1)
- MAX BRONSTEIN